Especially noteworthy is that targeting the TP53RK/Birc5 axis to retard renal fibrosis is of high translational probability, because the TP53RK inhibitor FA is a clinically commonly used antibiotic and Birc5 selective inhibitor YM‐155 is currently in clinical phase 2 trials. Here, TP53RK is linked to renal fibrosis.